<DOC>
	<DOCNO>NCT00088478</DOCNO>
	<brief_summary>Key objectives clinical study : - Determine well intramuscular ( IM ) olanzapine depot work compare placebo - Evaluate safety tolerability IM olanzapine depot compare placebo - Evaluate different dos IM olanzapine depot compare placebo identify best dose ( ) .</brief_summary>
	<brief_title>Comparison Intramuscular Olanzapine Depot With Placebo Treatment Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients must schizophrenia experience psychotic episode Each patient must level understanding sufficient complete test examination require protocol , provide informed consent Patient must participate clinical trial another investigational drug , include olanzapine , within 1 month ( 30 day ) prior study entry Female patient must pregnant breastfeed Female patient must experience acute , serious unstable medical condition schizophrenia Patients previously treat olanzapine consider treatmentresistant olanzapine , opinion investigator One seizures without clear resolve etiology exclusionary . However , patient one seizures past identifiable etiology , etiology resolve , patient may enter . Treatment clozapine within 4 week prior visit 1 DSMIV DSMIVTR substance ( except nicotine caffeine ) dependence within past 30 day Treatment remoxipride within 6 month ( 180 day ) prior visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>